Q32 Bio

Q32 Bio is a biotechnology company located in Cambridge, Massachusetts, dedicated to providing treatments for patients with severe autoimmune and inflammatory diseases. The company's pipeline includes a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R) and a complement therapeutic platform, which has generated fusion proteins that downregulate complement activity specific to disease-affected tissues. Q32 Bio’s most advanced program, ADX-914, is a fully human anti-IL-7R antibody, which has been licensed from Bristol Myers Squibb (NYSE: BMY) to modulate adaptive immune function.